🇺🇸 FDA
Patent

US 11866507

Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same

granted A61PA61P35/00

Quick answer

US patent 11866507 (Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same) held by Inhibrx, Inc. expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Inhibrx, Inc.
Grant date
Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61P, A61P35/00